414
Participants
Start Date
April 10, 2014
Primary Completion Date
May 27, 2015
Study Completion Date
March 28, 2018
Secukinumab
Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
Placebo
Secukinumab placebo provided in 1 mL autoinjector
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Fribourg
Novartis Investigative Site, Kogarah
Novartis Investigative Site, Malvern East
Novartis Investigative Site, Maroochydore
Novartis Investigative Site, Veliko Tarnovo
Novartis Investigative Site, Hobart
Novartis Investigative Site, Berlin
Novartis Investigative Site, Torino
Novartis Investigative Site, Albany
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Genova
Novartis Investigative Site, Duncansville
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Hildesheim
Novartis Investigative Site, Aventura
Novartis Investigative Site, Sarasota
Novartis Investigative Site, Palm Harbor
Novartis Investigative Site, Verona
Novartis Investigative Site, Santander
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Gommern
Novartis Investigative Site, Zerbst
Novartis Investigative Site, Bologna
Novartis Investigative Site, Seville
Novartis Investigative Site, Bowling Green
Novartis Investigative Site, Reggio Emilia
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Aachen
Novartis Investigative Site, St Louis
Novartis Investigative Site, Mesquite
Novartis Investigative Site, Austin
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Catania
Novartis Investigative Site, Wenatchee
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Sestroretsk
Novartis Investigative Site, Rostov-on-Don
Novartis Investigative Site, Saratov
Novartis Investigative Site, Chelyabinsk
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Freehold
Novartis Investigative Site, Victoria
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, Toronto
Novartis Investigative Site, Trois-Rivières
Novartis Investigative Site, Bruntál
Novartis Investigative Site, Prague
Novartis Investigative Site, Uherské Hradiště
Novartis Investigative Site, Chemnitz
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Heerlen
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Caguas
Novartis Investigative Site, Ponce
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, London
Novartis Investigative Site, Salford
Novartis Investigative Site, Cannock
Novartis Investigative Site, Stoke-on-Trent
Novartis Investigative Site, Barnsley
Novartis Investigative Site, Eastbourne
Novartis Investigative Site, Harrogate
Novartis Investigative Site, Hull
Novartis Investigative Site, London
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Novartis Investigative Site, Torquay
Novartis Investigative Site, Tyne and Wear
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY